Affimed (AFMD) Competitors $3.26 +0.03 (+0.93%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AFMD vs. PROC, ZNTL, FULC, DRUG, OGI, ZURA, SCLX, ATAI, DMAC, and ATOSShould you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Procaps Group (PROC), Zentalis Pharmaceuticals (ZNTL), Fulcrum Therapeutics (FULC), Bright Minds Biosciences (DRUG), Organigram (OGI), Zura Bio (ZURA), Scilex (SCLX), Atai Life Sciences (ATAI), DiaMedica Therapeutics (DMAC), and Atossa Therapeutics (ATOS). These companies are all part of the "pharmaceutical products" industry. Affimed vs. Procaps Group Zentalis Pharmaceuticals Fulcrum Therapeutics Bright Minds Biosciences Organigram Zura Bio Scilex Atai Life Sciences DiaMedica Therapeutics Atossa Therapeutics Affimed (NASDAQ:AFMD) and Procaps Group (NASDAQ:PROC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability. Does the media favor AFMD or PROC? In the previous week, Affimed had 3 more articles in the media than Procaps Group. MarketBeat recorded 3 mentions for Affimed and 0 mentions for Procaps Group. Affimed's average media sentiment score of 0.57 beat Procaps Group's score of 0.00 indicating that Affimed is being referred to more favorably in the media. Company Overall Sentiment Affimed Positive Procaps Group Neutral Do analysts rate AFMD or PROC? Affimed presently has a consensus target price of $20.00, suggesting a potential upside of 513.50%. Given Affimed's higher probable upside, equities research analysts clearly believe Affimed is more favorable than Procaps Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Affimed 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Procaps Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has stronger earnings and valuation, AFMD or PROC? Procaps Group has higher revenue and earnings than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAffimed$2.68M18.49-$114.66MN/AN/AProcaps Group$409.92MN/A$42.54M$0.523.43 Do insiders & institutionals have more ownership in AFMD or PROC? 30.8% of Affimed shares are owned by institutional investors. 3.8% of Affimed shares are owned by insiders. Comparatively, 19.9% of Procaps Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is AFMD or PROC more profitable? Procaps Group has a net margin of 0.00% compared to Affimed's net margin of -2,922.74%. Procaps Group's return on equity of 0.00% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Affimed-2,922.74% -155.30% -92.65% Procaps Group N/A N/A N/A Which has more volatility & risk, AFMD or PROC? Affimed has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Procaps Group has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Does the MarketBeat Community believe in AFMD or PROC? Affimed received 432 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 70.16% of users gave Affimed an outperform vote while only 37.50% of users gave Procaps Group an outperform vote. CompanyUnderperformOutperformAffimedOutperform Votes43570.16% Underperform Votes18529.84% Procaps GroupOutperform Votes337.50% Underperform Votes562.50% SummaryAffimed beats Procaps Group on 8 of the 14 factors compared between the two stocks. Ad Timothy SykesThe most productive 1 min of your day… This next step in your trading career is a simple, yet important one. I want you to take 1 minute to sign up for FREE algo alerts powered by StocksToTrade.>> Click Here To Sign Up For StocksToTrade’s Algo Alerts << Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AFMD vs. The Competition Export to ExcelMetricAffimedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.64M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93114.8115.14Price / Sales18.49396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book0.785.324.665.02Net Income-$114.66M$153.56M$119.06M$225.46M7 Day Performance-1.95%0.13%0.80%0.37%1 Month Performance-0.91%15.23%5.65%3.57%1 Year Performance-6.86%41.14%36.75%29.43% Affimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AFMDAffimed3.7626 of 5 stars$3.26+0.9%$20.00+513.5%-8.3%$49.64M$2.68M0.0076News CoveragePROCProcaps Group0.5874 of 5 stars$1.80-4.8%N/A-35.3%$203.08M$414.10M3.465,500Gap DownZNTLZentalis Pharmaceuticals1.5732 of 5 stars$2.84+0.4%$10.78+279.5%-79.7%$201.95MN/A-1.04160Upcoming EarningsFULCFulcrum Therapeutics3.4943 of 5 stars$3.23-0.3%$9.33+189.0%-14.4%$201.56M$81.63M-9.23100Upcoming EarningsShort Interest ↓Positive NewsDRUGBright Minds Biosciences1.1803 of 5 stars$45.10-5.3%N/A+3,416.8%$199.97MN/A-66.32N/AOGIOrganigram0.6422 of 5 stars$1.83-2.7%N/A+68.0%$198.71M$161.08M-4.36860Positive NewsZURAZura Bio2.5928 of 5 stars$4.45-3.5%$17.33+289.5%-6.8%$193.99MN/A0.003High Trading VolumeSCLXScilex2.8666 of 5 stars$0.99+1.1%$11.33+1,041.4%-46.3%$190.43M$46.74M-0.6980Gap UpATAIAtai Life Sciences2.0102 of 5 stars$1.13-7.4%$10.50+829.2%-9.2%$189.17M$378,000.00-2.8283Positive NewsDMACDiaMedica Therapeutics1.6105 of 5 stars$4.32+0.5%$7.00+62.0%+86.4%$184.67MN/A-8.1520Positive NewsATOSAtossa Therapeutics1.1609 of 5 stars$1.43-1.4%$6.25+337.1%+110.3%$179.83MN/A-6.818Analyst ForecastNews Coverage Related Companies and Tools Related Companies PROC Competitors ZNTL Competitors FULC Competitors DRUG Competitors OGI Competitors ZURA Competitors SCLX Competitors ATAI Competitors DMAC Competitors ATOS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AFMD) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.